Tesamorelin + Ipamorelin vs Sermorelin

Tesamorelin + Ipamorelin wins for:

• Potency: Superior IGF-1 elevation and specifically validated visceral fat reduction (VAT) per documented Phase III data (tesamorelin).
• Synergy: Dual-receptor stimulation yields higher, yet still physiologic, GH pulses versus GHRH-only.
• Recomp/advanced outcomes: Better for cutting phases, potent VAT bias, and preserving lean mass alongside GLP-1s or aggressive deficits.

Sermorelin wins for:

• Safety/tolerability: Minimal side effect profile, extremely low risk of edema, insulin resistance, or negative feedback suppression.
• Accessibility and cost: Broadly available, easier to source, and less expensive. Simple, forgiving dosing with fewer storage/reconstitution quirks.
• General well-being: Ideal for long-run recovery, joint support, and slow-burn anti-aging outcomes where aggressive recomposition is not the main goal.

Pick Tesamorelin + Ipamorelin if:

• VAT (visceral fat) reduction is a top priority—especially in recomp, contest-prep, or visible midsection cuts.
• IGF-1 targets are notably low and a significant boost is required for tissue healing, recovery, or aesthetics.
• Running aggressive deficit protocols or GLP-1 agonists, and lean mass preservation is critical.
• Looking for HGH-like outcomes (fat loss, recovery, sleep) without overt GH sides (edema, acromegalic features).
• Willing to manage more finicky reconstitution and handle slightly higher per-protocol costs for advanced results.

Pick Sermorelin if:

• Seeking a conservative, entry-level GH-axis upregulation with strong safety margins and negligible risk profile.
• Interested mainly in improved sleep, recovery, slow skin improvement, or joint maintenance.
• Prioritizing simplicity, cost-efficiency, and broad availability in sourcing.
• Using as a bridge between cycles or as a low-side-effect longevity/looksmaxxing protocol.
• Want a gentle, feedback-regulated GH pulse without needing lab-level reconstitution storage discipline.